Evidence map›Paper›PMID 23103995›Full record

ReviewAmerican journal of respiratory cell and molecular biology2013

Cystic fibrosis therapy: a community ecology perspective.

Douglas Conrad, Matthew Haynes, Peter Salamon, Paul B Rainey, Merry Youle, Forest Rohwer

Abstract readReview
In one paragraph

Review in American journal of respiratory cell and molecular biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 106 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Fungal lung disease.The European respiratory journal · 2024
    Review
  6. Review
  7. Article
  8. Journal of fungi (Basel, Switzerland) · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. What Makes Pseudomonas aeruginosa a Pathogen?Advances in experimental medicine and biology · 2022
    Article
  17. Review
  18. Multi-Omics Study of Keystone Species in a Cystic Fibrosis Microbiome.International journal of molecular sciences · 2021
    Article
  19. The Gut-Lung Axis in Cystic Fibrosis.Journal of bacteriology · 2021
    Review
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Douglas ConradDivision of Pulmonary and Critical Care Medicine, University of California at San Diego, San Diego Veterans Administration Healthcare System, 3350 La Jolla Village Drive, 111J, San Diego, CA 92122, USA. dconrad@ucsd.edu
Matthew Haynes
Peter Salamon
Paul B Rainey
Merry Youle
Forest Rohwer
Allan Wilson Centre · NZJoint Genome Institute · USSan Diego State University · USVA San Diego Healthcare System · US

Funding

Ecology of Cystic Fibrosis: Administrative SupplementR01GM095384 · NIGMS · SAN DIEGO STATE UNIVERSITY · PI ROHWER, FOREST L · 2011 to 2014
$1.9M
NIGMS NIH HHS R01 GM095384PHS HHS R01 56586A
6 · The paper itself

Abstract

Current therapy for cystic fibrosis (CF) focuses on minimizing the microbial community and the host's immune response through the aggressive use of airway clearance techniques, broad-spectrum antibiotics, and treatments that break down the pervasive endobronchial biofilm. Antibiotic selection is typically based on the susceptibility of individual microbial strains to specific antibiotics in vitro. Often this approach cannot accurately predict medical outcomes because of factors both technical and biological. Recent culture-independent assessments of the airway microbial and viral communities demonstrated that the CF airway infection is considerably more complex and dynamic than previously appreciated. Understanding the ecological and evolutionary pressures that shape these communities is critically important for the optimal use of current therapies (in both the choice of therapy and timing of administration) and the development of newer strategies. The climax-attack model (CAM) presented here, grounded in basic ecological principles, postulates the existence of two major functional communities. The attack community consists of transient viral and microbial populations that induce strong innate immune responses. The resultant intense immune response creates microenvironments that facilitate the establishment of a climax community that is slower-growing and inherently resistant to antibiotic therapy. Newer methodologies, including sequence-based metagenomic analysis, can track not only the taxonomic composition but also the metabolic capabilities of these changing viral and microbial communities over time. Collecting this information for CF airways will enable the mathematical modeling of microbial community dynamics during disease progression. The resultant understanding of airway communities and their effects on lung physiology will facilitate the optimization of CF therapies.

Indexed as

Anti-Bacterial AgentsBacteriaCystic FibrosisHumansAnti-Bacterial Agents

Identifiers

PMID23103995
PMCPMC3604065
OpenAlexW2163792002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.